GlassScriptPhysician profile
Joanne M Waltman
NPI 1063692739
$4,285.65
in general payments reported to CMS, 2019-2025
43 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $215 · 2021: $284 · 2022: $615 · 2023: $1,065 · 2024: $879 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.24 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $775.31 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $646.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $457.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $421.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.68 | 2019-2025 | Jardiance |
| Amgen INC. | $179.05 | 2020-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $132.22 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $115.77 | 2022-2024 | Vraylar |
| Phathom Pharmaceuticals, INC. | $97.70 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $94.87 | 2020-2024 | Belsomra, Verquvo, Steglatro |
| Sumitomo Pharma America, INC. | $90.76 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $87.27 | 2019-2020 | |
| Averitas Pharma INC. | $67.05 | 2024-2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $61.08 | 2022-2023 | |
| Nevro Corp. | $60.60 | 2022-2024 | Senza |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Waltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.